Alumis

Graphic image of an arrow nailing the bullseye of a target
Biotech

Alumis beams as pivotal data on Sotyktu rival drive stock surge

Phase 3 psoriasis studies of Alumis’ TYK2 inhibitor hit their primary endpoints, setting the biotech up to file for approval of a Sotyktu challenger.
Nick Paul Taylor Jan 6, 2026 9:05am
parasailing over clouds in Salzburg Austria

Sarepta shakes up C-suite amid org overhaul—Chutes & Ladders

Jul 18, 2025 8:30am
merge MA railway train tracks path together

Activist investor fails to derail Alumis' Acelyrin merger

May 14, 2025 7:45am
Graphic image of a red thumbs down against a blue background

Investor pressures Acelyrin to exit Alumis merger and liquidate

Apr 30, 2025 10:30am
puzzle pact

Kaken pens $180M pact for Alumis' lead TYK2 inhibitor in Japan

Mar 25, 2025 6:55am
blocks with checks and crosses

Acelyrin turns down surprise Concentra buyout offer

Mar 4, 2025 10:26am